A Fair Amount of ARPA-H Funding is Being Used for Clinical Trials Relevant to Aging
The US Advanced Research Projects Agency for Health (ARPA-H) is directing up to $144 million through its PROSPR program to advance human trials that treat aging as a tractable biological process by using longitudinal biomarkers as surrogate endpoints. Grants include up to $30.8 million to Cambrian for a next-generation rapamycin analog targeting mTORC1 and up to $22 million to Linnaeus for a G protein-coupled estrogen receptor (GPER) drug. The approach aims to show measurable healthspan shifts within one to three years and highlights companies exploring lower-cost trial geographies and medical-tourism pathways.
Why it mattersARPA-H is allocating up to $144 million via PROSPR to biomarker-driven geroscience trials.
Entities Mentioned
ARPA-HCambrian